Fed. Circ. Backs PTAB Ax Of J&J Prostate Cancer Drug Patent

Law360 (May 14, 2019, 6:11 PM EDT) -- The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating a patent on Johnson & Johnson’s blockbuster prostate cancer drug Zytiga, while leaving open a larger question about the reach of estoppel in America Invents Act reviews.

The appeals court passed on an opportunity to address an argument from J&J unit Janssen that companies successful in invalidating a patent in inter partes review cannot repeat their winning arguments in district court. The U.S. Patent and Trademark Office backed this position.

Instead, the Federal Circuit court upheld a 2018 PTAB decision in a review requested by Wockhardt Bio...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

November 1, 2018

Law Firms

Companies

Government Agencies

Patents

Judge Analytics